Breast cancer news

People over 70 better tolerate radiation therapy to hormonal therapy according to results from the phase III clinical trial EUROPA.

Promising ctDNA study to help understand risk of recurrence in TNBC and BRCA-positive early breast cancer ends due to low enrollment. This discontinued study suggests potential for liquid biopsy to guide treatment and offers takeaways for future research.

Adding palbociclib to standard treatment results in average of 44.3 months without cancer growth or spread in HER2-positive, HR-positive metastatic breast cancer.

Active monitoring may be a safe option for some people with low-risk DCIS, according to early results from the COMET study. At two years, outcomes were similar to treatment, but more follow-up is needed.

Imlunestrant proves effective against hormone receptor-positive, HER2-negative advanced breast cancer in the EMBER3 trial.

People with breast cancer need more information and, in some cases, better research around sexuality, physical activity, diet, and dietary supplements including cannabis.